Candel Therapeutics

This #Movember, the Candel team joins the global initiative supporting men's health awareness. As we advance phase 2 and phase 3 clinical trials in prostate cancer, we're committed to making a meaningful impact in men's healthcare. ? Our team proudly supports this important cause. Together, we work toward better outcomes for men's wellbeing. ? https://us.movember.com/ ? #MensHealth #ProstateCancer #ClinicalTrials?

This #Movember, the Candel team joins the global initiative supporting men's health awareness. As we advance phase 2 and phase 3 clinical trials in prostate cancer, we're committed to making a meaningful impact in men's healthcare. ? Our team proudly supports this important cause. Together, we work toward better outcomes for men's wellbeing. ? https://us.movember.com/ ? #MensHealth #ProstateCancer #ClinicalTrials?

Could CAN-2409 change how we treat localized #ProstateCancer? Our phase 3 clinical trial evaluates whether experimental treatment with CAN-2409 added to standard of care radiotherapy results in more patients with intermediate-high risk prostate cancer achieving disease-free survival. The trial is conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Learn more: https://lnkd.in/evZ7S6Zv #ClinicalTrials #ClinicalResearch #BioTech #Immunotherapy

Our President and CEO, Paul Peter Tak, MD PhD FMedSci, recently sat down with Proactive Investors. In the interview he discussed our upcoming prostate cancer trial readouts for CAN-2409 and highlighted promising developments with CAN-3110 in #glioblastoma and #melanoma. Watch the full interview: https://lnkd.in/e3w8Vn42? ? #BiotechNews #CancerResearch #Immunotherapy #prostatecancer?

Did you know??CAN-2409, our investigational viral immunotherapy, is designed to help stimulate the body’s immune response against cancer. When combined with valacyclovir, it?activates the immune system that may help fight tumor cells.?? ? We're studying CAN-2409's potential to improve disease outcomes in prostate cancer?while maintaining quality of life. Stay tuned for updates later this year.?? ? Learn how CAN-2409 works: https://lnkd.in/eN7KM7Di ? #CancerTreatment #ClinicalTrials #ImmunotherapyResearch #CancerImmunotherap

For men diagnosed with localized prostate cancer, treatment decisions can be complex. While active surveillance helps avoid over-treatment in low-risk disease, many patients will still experience disease progression. At Candel, we're investigating new approaches that could potentially bridge this gap through our clinical trials in localized prostate cancer. Learn more: https://lnkd.in/evZ7S6Zv

This World Pancreatic Cancer Day, we're highlighting our phase 2 clinical trial of CAN-2409, our investigational viral immunotherapy, combined with standard of care in patients with borderline resectable pancreatic cancer.? ? Patients receiving CAN-2409 achieved estimated median overall survival of 28.8. months, with more than 70% survival at two-years, compared to 12.5 months and nearly 17% in the control group that received standard of care only. CAN-2409 works by in situ vaccination against the patient’s tumor and fundamentally changing the tumor's microarchitecture, potentially offering new hope for pancreatic cancer patients.? ? CAN-2409 previously received FDA Fast Track Designation and Orphan Drug Designation.? ? Learn more about our approach: https://lnkd.in/dGPghctu?? ? #WorldPancreaticCancerDay #CancerResearch #PancreaticCancer #ClinicalTrials?

We are attending! Paul Peter Tak, MD PhD FMedSci President and CEO, is delivering a keynote at the British Society for Immunology (BSI) Immune Therapies Summit next week in Cambridge! He'll be discussing our work on viral immunotherapy as a novel approach to inducing systemic anti-tumor immunity. We are looking forward to engaging discussions and sharing insights with colleagues. https://lnkd.in/eqDHHn4P #Immunology #CancerResearch #Biotechnology #BSIImmunoTherapies24

Candel is conducting a phase 2b clinical trial in prostate cancer to evaluate CAN-2409, our lead asset, in patients with low-to-intermediate risk disease who are undergoing active surveillance. The trial aims to assess whether CAN-2409 administration could stop disease progression. Learn more: https://lnkd.in/evZ7S6Zv #Oncology #ProstateCancer #MedicalResearch #ClinicalResearch #ClinicalTrials

Paul Peter Tak, MD PhD FMedSci, President and CEO, will share the latest corporate updates at the Jefferies London Healthcare Conference this week.? ? We invite you to tune in to the live or archived presentation here: https://lnkd.in/e4eZQJnk? ? #JefferiesHealthcare #Biotechnology??